Stock Scorer

ALNYLAM PHARMACEUTICALS, INC. (ALNY)

ALNYLAM PHARMACEUTICALS, INC. reported revenue of 1.3B USD for the quarter ending 30 June 2026, up 117.3% from 594.2M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 1.3B +117.3%
Gross Profit Q2 '26 · ending 30 June 2026 992.7M +89.4%
Operating Income Q2 '26 · ending 30 June 2026 231.4M +1180.3%
Net Income Q2 '26 · ending 30 June 2026 164.5M —
Cost of Revenue Q2 '26 · ending 30 June 2026 298.3M +325.0%
Operating Cash Flow Q4 '25 · ending 31 December 2025 163.6M —
Free Cash Flow Q4 '25 · ending 31 December 2025 140.3M —
Shares Outstanding Q2 '26 · ending 30 June 2026 138.3M +7.5%
EPS Q4 '24 · ending 31 December 2024 -2.17 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 3.7B501.6M313.7M465.4M
20242024-12-31 2.2B-176.9M-278.2M-42.6M
20232023-12-31 1.8B-282.2M-440.2M41.9M
20222022-12-31 1B-785.1M-1.1B-613.3M
20212021-12-31 844.3M-708.7M-852.8M-718.1M
20202020-12-31 492.9M-828.4M-858.3M-685.3M
20192019-12-31 219.8M-939.4M-886.1M-418.6M
20182018-12-31 74.9M-814.7M-761.5M-689.5M
20172017-12-31 89.9M-500.1M-490.9M-487M
20162016-12-31 47.2M-424.6M-410.1M-372.3M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-301.3B
Q4 '252025-12-311.1B
Q3 '252025-09-301.2B
Q2 '252025-06-30773.7M
Q1 '252025-03-31594.2M
Q4 '242024-12-31593.2M
Q3 '242024-09-30500.9M
Q2 '242024-06-30659.8M
Q1 '242024-03-31494.3M
Q4 '232023-12-31439.7M
Q3 '232023-09-30750.5M
Q2 '232023-06-30318.8M
Q1 '232023-03-31319.3M
Q4 '222022-12-31335M
Q3 '222022-09-30264.3M
Q2 '222022-06-30224.8M
Q1 '222022-03-31213.3M
Q4 '212021-12-31258.5M
Q3 '212021-09-30187.6M
Q2 '212021-06-30220.6M

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q2 '262026-06-30992.7M
Q4 '252025-12-31829.3M
Q3 '252025-09-301.1B
Q2 '252025-06-30631.7M
Q1 '252025-03-31524M
Q4 '242024-12-31490.5M
Q3 '242024-09-30418.9M
Q2 '242024-06-30592.6M
Q1 '242024-03-31439.7M
Q4 '232023-12-31367.7M
Q3 '232023-09-30671.1M
Q2 '232023-06-30243.4M
Q1 '232023-03-31277.9M
Q4 '222022-12-31288.9M
Q3 '222022-09-30227.8M
Q2 '222022-06-30190.8M
Q1 '222022-03-31189.8M
Q4 '212021-12-31224.9M
Q3 '212021-09-30159.5M
Q2 '212021-06-30190.3M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30231.4M
Q4 '252025-12-31131.7M
Q3 '252025-09-30368M
Q2 '252025-06-30-16.2M
Q1 '252025-03-3118.1M
Q4 '242024-12-31-105.2M
Q3 '242024-09-30-76.9M
Q2 '242024-06-3048.6M
Q1 '242024-03-31-43.4M
Q4 '232023-12-31-116.4M
Q3 '232023-09-30213.9M
Q2 '232023-06-30-229.8M
Q1 '232023-03-31-149.8M
Q4 '222022-12-31-188.6M
Q3 '222022-09-30-258M
Q2 '222022-06-30-191.7M
Q1 '222022-03-31-146.7M
Q4 '212021-12-31-194.6M
Q3 '212021-09-30-181.7M
Q2 '212021-06-30-146.2M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30164.5M
Q1 '262026-03-31206M
Q4 '252025-12-31111.5M
Q3 '252025-09-30251.1M
Q2 '252025-06-30-72.2M
Q1 '252025-03-31-18.3M
Q4 '242024-12-31-83.8M
Q3 '242024-09-30-111.6M
Q2 '242024-06-30-16.9M
Q1 '242024-03-31-65.9M
Q4 '232023-12-31-137.9M
Q3 '232023-09-30147.8M
Q2 '232023-06-30-276M
Q1 '232023-03-31-174.1M
Q4 '222022-12-31-207.5M
Q3 '222022-09-30-405.9M
Q2 '222022-06-30-277.4M
Q1 '222022-03-31-240.3M
Q4 '212021-12-31-258.5M
Q3 '212021-09-30-204.5M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-30298.3M
Q4 '252025-12-31267.7M
Q3 '252025-09-30197.2M
Q2 '252025-06-30142M
Q1 '252025-03-3170.2M
Q4 '242024-12-31102.6M
Q3 '242024-09-3082M
Q2 '242024-06-3067.3M
Q1 '242024-03-3154.6M
Q4 '232023-12-3172M
Q3 '232023-09-3079.5M
Q2 '232023-06-3075.3M
Q1 '232023-03-3141.4M
Q4 '222022-12-3146.2M
Q3 '222022-09-3036.5M
Q2 '222022-06-3034M
Q1 '222022-03-3123.5M
Q4 '212021-12-3133.6M
Q3 '212021-09-3028.1M
Q2 '212021-06-3030.3M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q4 '252025-12-31163.6M
Q3 '252025-09-30351M
Q2 '252025-06-30127.8M
Q1 '252025-03-31-118.3M
Q4 '242024-12-31-94.7M
Q3 '242024-09-3043.7M
Q2 '242024-06-30124.2M
Q1 '242024-03-31-81.5M
Q4 '232023-12-31-29.8M
Q3 '232023-09-30359.4M
Q2 '232023-06-30-59M
Q1 '232023-03-31-166.5M
Q4 '222022-12-31-132M
Q3 '222022-09-30-115.3M
Q2 '222022-06-30-122.8M
Q1 '222022-03-31-171.2M
Q4 '212021-12-31-150.1M
Q3 '212021-09-30-134M
Q2 '212021-06-30-121.9M
Q1 '212021-03-31-235.7M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '252025-12-31140.3M
Q3 '252025-09-30338.9M
Q2 '252025-06-30113.5M
Q1 '252025-03-31-127.3M
Q4 '242024-12-31-103.8M
Q3 '242024-09-3039.5M
Q2 '242024-06-30116.1M
Q1 '242024-03-31-94.5M
Q4 '232023-12-31-45.1M
Q3 '232023-09-30342.3M
Q2 '232023-06-30-74.9M
Q1 '232023-03-31-180.4M
Q4 '222022-12-31-153.6M
Q3 '222022-09-30-131.8M
Q2 '222022-06-30-138.9M
Q1 '222022-03-31-189.1M
Q4 '212021-12-31-172M
Q3 '212021-09-30-160.1M
Q2 '212021-06-30-133.1M
Q1 '212021-03-31-252.8M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30138.3M
Q3 '252025-09-30137.3M
Q2 '252025-06-30130.6M
Q1 '252025-03-31129.7M
Q3 '242024-09-30128.6M
Q2 '242024-06-30126.7M
Q1 '242024-03-31126.1M
Q3 '232023-09-30131.3M
Q2 '232023-06-30124.7M
Q1 '232023-03-31124.1M
Q3 '222022-09-30122.2M
Q2 '222022-06-30120.9M
Q1 '222022-03-31120.4M
Q3 '212021-09-30119.1M
Q2 '212021-06-30117.8M
Q1 '212021-03-31117.1M
Q3 '202020-09-30116M
Q2 '202020-06-30114.9M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q4 '242024-12-31-2.17
Q3 '242024-09-30-2.61
Q2 '242024-06-30-0.59
Q1 '242024-03-31-2.67
Q4 '232023-12-31-3.55
Q3 '232023-09-30-4.14
Q2 '232023-06-30-8.61
Q1 '232023-03-31-8.69
Q4 '222022-12-31-9.29
Q3 '222022-09-30-9.77
Q2 '222022-06-30-8.17
Q1 '222022-03-31-7.49
Q4 '212021-12-31-7.20
Q3 '212021-09-30-7.13
Q2 '212021-06-30-7.59
Q1 '212021-03-31-7.54
Q4 '202020-12-31-7.45
Q3 '202020-09-30-7.83
Q2 '202020-06-30-7.57
Q1 '202020-03-31-8.03